All questions
Clinical trials: Stelara (ustekinumab) in plaque psoriasis 7 questions · 2 sources
Questions that apply to every indication of Stelara are on Stelara (ustekinumab), all indications .
Clinical trials How were the Stelara adult plaque psoriasis trials designed? Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
“Two multicenter, randomized, double-blind, placebo-controlled trials (Ps STUDY 1
and Ps STUDY 2) enrolled a total of 1996 subjects 18 years of age and older with
plaque psoriasis who had a minimum body surface area involvement of 10%, and
Psoriasis Area and Severity Index (PASI) score ≥12, and who were candidates
for phototherapy or systemic therapy. Subjects with guttate, erythrodermic, or
pustular psoriasis were excluded from the trials.
Ps STUDY 1 enrolled 766 subjects and Ps STUDY 2 enrolled 1230 subjects. The trials
had the same design through Week 28. In both trials, subjects were randomized
in equal proportion to placebo, 45 mg or 90 mg of STELARA. Subjects randomized
to STELARA received 45 mg or 90 mg doses, regardless of weight, at Weeks 0, 4,
and 16. Subjects randomized to receive placebo at Weeks 0 and 4 crossed over to
receive STELARA (either 45 mg or 90 mg) at Weeks 12 and 16.” (opens the source at this quote in a new tab) Copy Flag
Who was enrolled in the Stelara adult plaque psoriasis trials? Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Study results How effective is Stelara for plaque psoriasis at 12 weeks (PHOENIX 1 and 2)? Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Note: The prescribing information reports the adult trials as Ps STUDY 1 and Ps STUDY 2; its Week 12 counts match those the HCP site gives for PHOENIX 1 and PHOENIX 2. Table 12 columns are placebo, STELARA 45 mg, and STELARA 90 mg for each trial.
How many patients reached PASI 90 on Stelara at Week 12 (PHOENIX 2)? Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Subgroup results Does Stelara work as well in patients over 100 kg? Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Note: Table 13 columns are placebo, STELARA 45 mg, and STELARA 90 mg for each trial.
Maintenance of response What happens when Stelara is stopped after a response in plaque psoriasis? Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Pediatric efficacy How effective is Stelara for plaque psoriasis in children 12 and older? Applies to Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy